biotech

Bio-Analyst

Research Platform
person
arrow_backExplore/Quercetin
Tier-CPublic-ready6/28/2026

Quercetin

Blood pressure and vascular health markers is closer to a research marker, so it should be read separately from a directly felt benefit.

The 66.0 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the C tier remains conservative.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed
99
Caution signal
Low
Context-specific research signal
66.0
Blood pressure and vascular health markersCholesterol and triglyceridesImmune and respiratory support

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Blood pressure and vascular health
6 studiesTier-B
Blood pressure and vascular health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
58.5
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood lipids
5 studiesTier-B
Cholesterol and triglycerides
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.

Evidence score
56.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Immune and respiratory health
4 studiesTier-B
Immune and respiratory support
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Immune and respiratory health. These findings come from a defined study population, so everyday effects may differ.

Evidence score
54.6
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Men's health
2 studiesTier-C
Male Reproductive Health Markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

These findings come from sperm, semen, or hormone markers such as testosterone, LH, FSH, and inhibin B. They are closer to research measurements than a directly felt benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
48.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Women's health
2 studiesTier-C
Menstrual and women's health
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.

Evidence score
48.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Glucose and metabolic health
7 studiesTier-C
Glucose and metabolic health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
45.2
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Observed range in repeated studies

This range includes studies in specific patient groups. It is not a general dose or recommendation.

Lower observed study value
15.5
mg/day
Higher observed study value
1000
mg/day
Only ranges repeated in human, oral, single-ingredient studies are shown.
Not personal dosing instructions, recommendations, or safety limits.

Key cautions to review

Standalone side-effect signals and combination cautions are listed separately.

Caution index
0.6
Caution band: Low
Caution signals
0
Side effects + combos + curated rules
Key precautions
No combination caution signal is clear enough to show right now. This does not guarantee safety.
Standalone side effects, combination cautions, and positive combos are separated below.

Side-effect and combination signals

No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1
Public scholarly dataCitation signal: 1129
observational

“Hit-and-run” treatment with senolytics, which in the case of D’+ Q have elimination half-lives <11 h, significantly decreases senescent cell burden in humans.

Key Evidence #2
Public scholarly dataCitation signal: 865
review

Although deficiencies in polyphenol intake do not result in specific deficiency diseases, adequate intake of polyphenols could confer health benefits, especially with regard to chronic diseases, because tea, cocoa, fruits, and berries, as well as vegetables, a

Key Evidence #3
Public scholarly dataCitation signal: 695
review

It is possible that a lower dosage from plant sources could be effective due to of its higher bioavailability compared to the aglycone form, and studies are needed to evaluate the potential cardiovascular benefits of plants rich in quercetin and kaempferol gly

3 more summariesLimited representative sample by study type.
>
Public scholarly dataCitation signal: 523
review

Quercetin’s anti-inflammatory properties involve inhibiting the production of inflammatory cytokines and enzymes, making it a potential therapeutic agent for various inflammatory conditions, and it exhibits anticancer effects by inhibiting cancer cell prolifer

Public scholarly dataCitation signal: 454
review

The antimicrobial activity of quercetin is summarized with a special focus on its mechanistic principle, and the implications for its use as a clinically relevant antimicrobial agent are summarized.

Public scholarly dataCitation signal: 374
observational

It is indicated that quercetin showing inhibitory activity in the early stage of influenza infection provides a future therapeutic option to develop effective, safe and affordable natural products for the treatment and prophylaxis of IAV infections.

Quercetin
arrow_backBack to list